Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing

Journal of Clinical Microbiology

Volumn 52, Issue 7, 2014, Pages 2320-2327

  Beck, Ingrid A ^a   Deng, Wenjie ^b   Payant, Rachel ^a   Hall, Robert ^b   Bumgarner, Roger E ^b   Mullins, James I ^b   Frenkel, Lisa M ^a,b,c  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS DNA; VIRUS RNA; DNA LIGASE; OLIGONUCLEOTIDE;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD LEVEL; CODON; CONTROLLED STUDY; GENE IDENTIFICATION; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INVESTIGATIVE PROCEDURES; KENYA; MOZAMBIQUE; NONHUMAN; OLIGONUCLEOTIDE LIGATION ASSAY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; RNA STRUCTURE; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SPECIES COMPARISON; VALIDATION PROCESS; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS MUTANT; ADULT; DIAGNOSTIC ERROR; DRUG EFFECTS; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MICROBIAL SENSITIVITY TEST; MOLECULAR DIAGNOSIS; PROCEDURES; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; VIROLOGY;

ADULT; DIAGNOSTIC ERRORS; DNA LIGASES; DRUG RESISTANCE, VIRAL; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; INFANT; KENYA; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOZAMBIQUE; OLIGONUCLEOTIDES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84903752493     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00306-14     Document Type: Article

References (47)

1. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, Sanders EJ, Bekker LG, Twesigye R, Hunter E, Kaleebu P, Kayitenkore K, Allen S, Ruzagira E, Mwangome M, Mutua G, Amornkul PN, Stevens G, Pond SL, Schaefer M, Papathanasopoulos MA, Stevens W, Gilmour J. 2011. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res. Hum. Retroviruses 27:5-12. http://dx.doi.org/10.1089/aid.2010. 0030.
2. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Gregson J, Sawyer AW, Hamers RL, Ndembi N, Pillay D, Bertagnolio S. 2012. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 380:1250-1258. http://dx.doi.org/10. 1016/S0140-6736(12)61038-1.
3. Stadeli KM, Richman DD. 2013. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir. Ther. 18: 115-123. http://dx.doi.org/10.3851/IMP2437.
4. Department of Health and Human Services. 2013. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC.
5. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, de Luca A, Palmisano L, Paraskevis D, Paredes R, Poljak M, Schmit JC, Soriano V, Walter H, Sonnerborg A. 2011. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. 13:77-108.
6. Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, Geretti AM, Kelleher P, Mackie N, Muir D, Murphy G, Orkin C, Post F, Rooney G, Sabin C, Sherr L, Smit E, Tong W, Ustianowski A, Valappil M, Walsh J, Williams M, Yirrell D. 2012. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med. 13:1-44. http://dx.doi.org/10.1111/j.1468-1293.2011.00971.x.
7. Sayer DC, Land S, Gizzarelli L, French M, Hales G, Emery S, Christiansen FT, Dax EM. 2003. Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations. J. Clin. Microbiol. 41:227-236. http://dx.doi.org/10.1128/JCM.41.1.227-236.2003.
8. Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM, Frenkel LM, Hazelwood JD, Johnson VA, Kearney M, Kovacs A, Kuritzkes DR, Metzner KJ, Nissley DV, Nowicki M, Palmer S, Ziermann R, Zhao RY, Jennings CL, Bremer J, Brambilla D, Mellors JW. 2006. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J. Clin. Microbiol. 44:2612-2614. http://dx.doi.org/10.1128/JCM. 00449-06. (Pubitemid 44092442)
9. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, III, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM. 2008. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenzbased regimen in treatment-naive HIV-1-infected subjects. J. Infect. Dis. 197:867-870. http://dx.doi.org/10.1086/ 528802. (Pubitemid 351417010)
10. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, Heneine W. 2008. Minority HIV-1drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 5:e158. http://dx.doi.org/10.1371/journal.pmed.0050158.
11. Van Laethem K, De Munter P, Schrooten Y, Verbesselt R, Van Ranst M, Van Wijngaerden E, Vandamme AM. 2007. No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. J. Clin. Virol. 39:43-47. http://dx.doi.org/10.1016/j. jcv.2007.02.003. (Pubitemid 46575341)
12. Varghese V, Shahriar R, Rhee SY, Liu T, Simen BB, Egholm M, Hanczaruk B, Blake LA, Gharizadeh B, Babrzadeh F, Bachmann MH, Fessel WJ, Shafer RW. 2009. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 52:309-315. http://dx.doi.org/10.1097/QAI.0b013e3181bca669.
13. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR. 2011. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305:1327-1335. http://dx.doi.org/10.1001/jama.2011.375.
14. Boltz VF, Zheng Y, Lockman S, Hong F, Halvas EK, McIntyre J, Currier JS, Chibowa MC, Kanyama C, Nair A, Owino-Ong'or W, Hughes M, Coffin JM, Mellors JW. 2011. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc. Natl. Acad. Sci. U. S. A. 108: 9202-9207. http://dx.doi.org/10.1073/pnas. 1105688108.
15. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR, Kuritzkes DR. 2012. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 26:185-192. http://dx.doi.org/10.1097/ QAD.0b013e32834e9d7d.
16. Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM. 1998. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J. Clin. Microbiol. 36:569-572. (Pubitemid 28060333)
17. Beck IA, Mahalanabis M, Pepper G, Wright A, Hamilton S, Langston E, Frenkel LM. 2002. Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J. Clin. Microbiol. 40:1413-1419. http://dx.doi.org/10.1128/JCM.40.4.1413-1419.2002. (Pubitemid 34279910)
18. Beck IA, Crowell C, Kittoe R, Bredell H, Machaba M, Willamson C, Janssens W, Jallow S, van der Groen G, Shao Y, Jacob M, Samuel NM, de Rivera IL, Ngo-Giang-Huong N, Cassol S, Alemnji G, Frenkel LM. 2008. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J. Acquir. Immune Defic. Syndr. 48:418-427. http://dx.doi.org/10.1097/QAI.0b013e31817ed7d7.
19. Ellis GM, Mahalanabis M, Beck IA, Pepper G, Wright A, Hamilton S, Holte S, Naugler WE, Pawluk DM, Li CC, Frenkel LM. 2004. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J. Clin. Microbiol. 42:3670-3674. http://dx.doi.org/10.1128/JCM.42. 8.3670-3674.2004. (Pubitemid 39045698)
20. Flys TS, Chen S, Jones DC, Hoover DR, Church JD, Fiscus SA, Mwatha A, Guay LA, Mmiro F, Musoke P, Kumwenda N, Taha TE, Jackson JB, Eshleman SH. 2006. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J. Acquir. Immune Defic. Syndr. 42:610-613. http://dx.doi.org/10.1097/01.qai.0000221686. 67810.20.
21. Rowley CF, Boutwell CL, Lockman S, Essex M. 2008. Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C. J. Virol. Methods 149:69-75. http://dx.doi.org/10.1016/j.jviromet.2008.01.005.
22. Shi C, Eshleman SH, Jones D, Fukushima N, Hua L, Parker AR, Yeo CJ, Hruban RH, Goggins MG, Eshleman Jr. 2004. LigAmp for sensitive detection of single-nucleotide differences. Nat. Methods 1:141-147. http://dx.doi.org/10. 1038/nmeth713.
23. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, Berka J, Braverman MS, Chen YJ, Chen Z, Dewell SB, Du L, Fierro JM, Gomes XV, Godwin BC, He W, Helgesen S, Ho CH, Irzyk GP, Jando SC, Alenquer ML, Jarvie TP, Jirage KB, Kim JB, Knight JR, Lanza JR, Leamon JH, Lefkowitz SM, Lei M, Li J, Lohman KL, Lu H, Makhijani VB, McDade KE, McKenna MP, Myers EW, Nickerson E, Nobile JR, Plant R, Puc BP, Ronan MT, Roth GT, Sarkis GJ, Simons JF, Simpson JW, Srinivasan M, Tartaro KR, Tomasz A, Vogt KA, Volkmer GA, Wang SH, Wang Y, Weiner MP, Yu P, Begley RF, Rothberg JM. 2005. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437:376-380. http://dx.doi.org/10.1038/nature03959. (Pubitemid 41613494)
24. Hoffmann C, Minkah N, Leipzig J, Wang G, Arens MQ, Tebas P, Bushman FD. 2007. DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res. 35:e91. http://dx.doi.org/10.1093/nar/gkm435.
25. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ. 2009. Low-abundance drugresistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 199:693-701. http://dx.doi.org/10.1086/ 596736.
26. Lataillade M, Chiarella J, Yang R, DeGrosky M, Uy J, Seekins D, Simen B, St John E, Moreno E, Kozal M. 2012. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing. PLoS One 7:e30118. http://dx.doi.org/10. 1371/journal.pone.0030118.
27. Chung MH, Richardson BA, Tapia K, Benki-Nugent S, Kiarie JN, Simoni JM, Overbaugh J, Attwa M, John-Stewart GC. 2011. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med. 8:e1000422. http://dx.doi.org/10.1371/journal. pmed.1000422.
28. Micek MA, Blanco AJ, Beck IA, Dross S, Matunha L, Montoya P, Seidel K, Gantt S, Matediane E, Jamisse L, Gloyd S, Frenkel LM. 2010. Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin. Infect. Dis. 50:1405-1414. http://dx.doi.org/10.1086/652151.
29. Arvold ND, Ngo-Giang-Huong N, McIntosh K, Suraseranivong V, Warachit B, Piyaworawong S, Changchit T, Lallemant M, Jourdain G. 2007. Maternal HIV-1 DNA load and mother-to-child transmission. AIDS Patient Care STDS 21:638-643. http://dx.doi.org/10.1089/apc.2006.0169. (Pubitemid 47525386)
30. Beck IA, Drennan KD, Melvin AJ, Mohan KM, Herz AM, Alarcon J, Piscoya J, Velazquez C, Frenkel LM. 2001. Simple, sensitive, and specific detection of human immunodeficiency virus type 1 subtype B DNA in dried blood samples for diagnosis in infants in the field. J. Clin. Microbiol. 39:29-33. http://dx.doi.org/10.1128/JCM.39.1.29-33.2001. (Pubitemid 32059563)
31. Deng W, Maust BS, Westfall DH, Chen L, Zhao H, Larsen BB, Iyer S, Liu Y, Mullins JI. 2013. Indel and Carryforward Correction (ICC): a new analysis approach for processing 454 pyrosequencing data. Bioinformatics 29:2402-2409. http://dx.doi.org/10.1093/bioinformatics/btt434.
32. Liu TF, Shafer RW. 2006. Web resources for HIV type 1 genotypicresistance test interpretation. Clin. Infect. Dis. 42:1608-1618. http://dx.doi.org/10. 1086/503914.
33. Wallis CL, Mahomed I, Morris L, Chidarikire T, Stevens G, Rekhviashvili N, Stevens W. 2005. Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. J. Virol. Methods 125: 99-109. http://dx.doi.org/10.1016/j.jviromet.2005.01.004. (Pubitemid 40404017)
34. Gianella S, Delport W, Pacold ME, Young JA, Choi JY, Little SJ, Richman DD, Kosakovsky Pond SL, Smith DM. 2011. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J. Virol. 85:8359-8367. http://dx.doi.org/10.1128/JVI.02582-10.
35. Varghese V, Wang E, Babrzadeh F, Bachmann MH, Shahriar R, Liu T, Mappala SJ, Gharizadeh B, Fessel WJ, Katzenstein D, Kassaye S, Shafer RW. 2010. Nucleic acid template and the risk of a PCR-induced HIV-1 drug resistance mutation. PLoS One 5:e10992. http://dx.doi.org/10.1371 /journal.pone.0010992.
36. Rozera G, Abbate I, Bruselles A, Vlassi C, D'Offizi G, Narciso P, Chillemi G, Prosperi M, Ippolito G, Capobianchi MR. 2009. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 6:15. http://dx.doi.org/10.1186/1742-4690-6-15.
37. Huse SM, Huber JA, Morrison HG, Sogin ML, Welch DM. 2007. Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol. 8:R143. http://dx.doi.org/10.1186/gb-2007-8-7-r143.
38. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. 2007. Characterization of mutation spectra with ultra-deep pyrosequencing: ap-plication to HIV-1 drug resistance. Genome Res. 17:1195-1201. http://dx.doi.org/10.1101/gr.6468307. (Pubitemid 47204863)
39. Zagordi O, Klein R, Daumer M, Beerenwinkel N. 2010. Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies. Nucleic Acids Res. 38:7400-7409. http://dx.doi.org/10.1093/nar /gkq655.
40. Quince C, Lanzen A, Davenport RJ, Turnbaugh PJ. 2011. Removing noise from pyrosequenced amplicons. BMC Bioinformatics 12:38. http://dx.doi.org/10.1186/ 1471-2105-12-38.
41. Balzer S, Malde K, Jonassen I. 2011. Systematic exploration of error sources in pyrosequencing flowgram data. Bioinformatics 27:i304-i309. http://dx.doi.org/10.1093/bioinformatics/btr251.
42. Brodin J, Mild M, Hedskog C, Sherwood E, Leitner T, Andersson B, Albert J. 2013. PCR-induced transitions are the major source of error in cleaned ultra-deep pyrosequencing data. PLoS One 8:e70388. http://dx.doi.org/10.1371/ journal.pone.0070388.
43. Shao W, Boltz VF, Spindler JE, Kearney MF, Maldarelli F, Mellors JW, Stewart C, Volfovsky N, Levitsky A, Stephens RM, Coffin JM. 2013. Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology 10:18. http://dx.doi.org/10.1186/1742-4690-10-18.
44. Vandenbroucke I, Van Marck H, Verhasselt P, Thys K, Mostmans W, Dumont S, Van Eygen V, Coen K, Tuefferd M, Aerssens J. 2011. Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications. Biotechniques 51:167-77. http://dx.doi.org/10.2144/000113733.
45. Roberts JD, Bebenek K, Kunkel TA. 1988. The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173. http://dx.doi.org/10.1126/ science.2460925. (Pubitemid 19007043)
46. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. 2011. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc. Natl. Acad. Sci. U. S. A. 108:20166-20171. http://dx.doi.org/10.1073/pnas. 1110064108.
47. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA. 2012. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl. Acad. Sci. U. S. A. 109:14508-14513. http://dx.doi.org/10.1073/pnas.1208715109.